e-Therapeutics plc Appointment of Chief Financial Officer (7181T)
March 29 2021 - 1:00AM
UK Regulatory
TIDMETX
RNS Number : 7181T
e-Therapeutics plc
29 March 2021
e-therapeutics plc
("e-therapeutics" or the "Company")
Appointment of Chief Financial Officer
Oxford, UK, 29 March 2021: e-therapeutics plc (AIM: ETX.L) today
announces the appointment of Dr Karl Keegan as Chief Financial
Officer ("CFO") effective immediately. The CFO role will be a
non-board position.
Dr Keegan brings a depth of capital market and strategic
financing experience with over 20 years' experience in the
pharmaceutical and biotech industries. After working in academia
and large pharma, Karl became a highly rated sell-side analyst at a
number of investment banks. Since 2009, he has held senior
executive roles in private and public companies, most recently as
Chief Executive Officer of privately held Hox Therapeutics
Limited.
Karl received his BSc in Pharmacology from University College
Dublin, MPhil and PhD degrees from the University of Cambridge and
his MSc (Finance) from London Business School.
Dr Keegan, Chief Financial Officer, said: "I am delighted to be
joining the e-therapeutics team at such a pivotal time for the
Company. The Company has built an impressive computational biology
drug discovery platform and clinically validated RNA interference
drug modality."
Ali Mortazavi, Chief Executive Officer, commented: "We are
delighted to welcome Karl to e-therapeutics at this point in the
Company's evolution. The combination of his industry and financial
sector expertise will be a major addition to the team."
Enquiries:
e-therapeutics plc
Ali Mortazavi, CEO Tel: +44 (0)1993 883
125
www.etherapeutics.co.uk
SP Angel Corporate Finance LLP Tel: +44(0)20 3470
0470
Nominated Adviser and Broker
Matthew Johnson/Caroline Rowe (Corporate
Finance)
Vadim Alexandre/Rob Rees (Corporate Broking)
About e-therapeutics plc
e-therapeutics plc is an Oxford, UK-based company with a
powerful computer-based approach to drug discovery, founded on its
industry-leading expertise in network biology to fully capture
disease complexity. The Company combines network science, machine
learning, artificial intelligence, statistics and big data with
expertise in drug discovery and development to transform the search
for new medicines and intervention strategies.
e-therapeutics has developed an in silico laboratory that
enables the rapid screening of millions of compounds and the
identification of small sub-sets that are enriched for highly
active hits. Its proprietary platform also has novel applications
in functional genomics, being able to analyse complex genetic
datasets, provide a deep understanding of pathological mechanisms
and distil actionable insights for the discovery of novel drugs,
biomarkers and diagnostics.
e-therapeutics has deployed and validated its disease-agnostic
drug discovery platform both in house and with partners, including
Novo Nordisk, Galapagos NV and a US-based, top 5 pharmaceutical
company.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOABLGDXCSDDGBR
(END) Dow Jones Newswires
March 29, 2021 02:00 ET (06:00 GMT)
E-therapeutics (LSE:ETX)
Historical Stock Chart
From Mar 2024 to Apr 2024
E-therapeutics (LSE:ETX)
Historical Stock Chart
From Apr 2023 to Apr 2024
